Core Viewpoint - Company plans to acquire MicroPort Cardiac Rhythm Management for a total consideration of 680 million USD, enhancing its global cardiac product platform [1] Group 1: Acquisition Details - The acquisition will involve the issuance of approximately 3.95 billion new shares at an issue price of 1.35 HKD per share [1] - MicroPort Cardiac Rhythm Management specializes in solutions for arrhythmia management, providing devices to monitor cardiac information [1] Group 2: Strategic Implications - The acquisition is expected to create significant synergies by integrating resources in R&D, production, and sales, thereby strengthening the company's global competitiveness in cardiac treatment [1] - Post-acquisition, the target group will become a wholly-owned subsidiary of the company, with its financial performance consolidated into the company's results [1] Group 3: Shareholder Impact - The transaction requires approval from a special shareholder meeting and other conditions to be met [1] - MicroPort Medical, the controlling shareholder, currently holds approximately 46.12% of the company and will see its stake reduced to about 44.45% post-transaction, remaining the largest shareholder [1]
心通医疗-B(02160.HK)拟6.8亿美元以合并方式收购微创心率 强化公司在心脏病治疗领域的全球竞争